Progress  ||| S:0 E:9 ||| NN
in  ||| S:9 E:12 ||| IN
diabetes  ||| S:12 E:21 ||| JJ
Type  ||| S:21 E:26 ||| NNP
2  ||| S:26 E:28 ||| CD
diabetes  ||| S:28 E:37 ||| NN
mellitus  ||| S:37 E:46 ||| NN
is  ||| S:46 E:49 ||| VBZ
characterized  ||| S:49 E:63 ||| VBN
by  ||| S:63 E:66 ||| IN
insulin  ||| S:66 E:74 ||| NN
resistance  ||| S:74 E:85 ||| NN
and  ||| S:85 E:89 ||| CC
pancreatic  ||| S:89 E:100 ||| JJ
beta-cell  ||| S:100 E:110 ||| JJ
failure ||| S:110 E:117 ||| NN
.  ||| S:117 E:119 ||| .
Pancreatic  ||| S:119 E:130 ||| JJ
beta-cell  ||| S:130 E:140 ||| JJ
failure  ||| S:140 E:148 ||| NN
plays  ||| S:148 E:154 ||| VBZ
an  ||| S:154 E:157 ||| DT
important  ||| S:157 E:167 ||| JJ
role  ||| S:167 E:172 ||| NN
in  ||| S:172 E:175 ||| IN
the  ||| S:175 E:179 ||| DT
pathogenesis  ||| S:179 E:192 ||| NN
of  ||| S:192 E:195 ||| IN
diabetes  ||| S:195 E:204 ||| NN
in  ||| S:204 E:207 ||| IN
Japanese  ||| S:207 E:216 ||| JJ
subjects ||| S:216 E:224 ||| NNS
.  ||| S:224 E:226 ||| .
Several  ||| S:226 E:234 ||| JJ
mechanisms  ||| S:234 E:245 ||| NNS
underlying  ||| S:245 E:256 ||| VBG
the  ||| S:256 E:260 ||| DT
causes  ||| S:260 E:267 ||| NNS
of  ||| S:267 E:270 ||| IN
pancreatic  ||| S:270 E:281 ||| JJ
beta-cell  ||| S:281 E:291 ||| JJ
failure  ||| S:291 E:299 ||| NN
have  ||| S:299 E:304 ||| VBP
been  ||| S:304 E:309 ||| VBN
reported ||| S:309 E:317 ||| VBN
,  ||| S:317 E:319 ||| ,
including  ||| S:319 E:329 ||| VBG
decreased  ||| S:329 E:339 ||| JJ
insulin  ||| S:339 E:347 ||| NN
signaling ||| S:347 E:356 ||| NN
,  ||| S:356 E:358 ||| ,
endoplasmic  ||| S:358 E:370 ||| JJ
reticulum  ||| S:370 E:380 ||| JJ
stress ||| S:380 E:386 ||| NN
,  ||| S:386 E:388 ||| ,
oxidative  ||| S:388 E:398 ||| JJ
stress ||| S:398 E:404 ||| NN
,  ||| S:404 E:406 ||| ,
and  ||| S:406 E:410 ||| CC
inflammation ||| S:410 E:422 ||| NN
.  ||| S:422 E:424 ||| .
In  ||| S:424 E:427 ||| IN
addition ||| S:427 E:435 ||| NN
,  ||| S:435 E:437 ||| ,
the  ||| S:437 E:441 ||| DT
role  ||| S:441 E:446 ||| NN
of  ||| S:446 E:449 ||| IN
epigenetics  ||| S:449 E:461 ||| NN
in  ||| S:461 E:464 ||| IN
this  ||| S:464 E:469 ||| DT
association  ||| S:469 E:481 ||| NN
has  ||| S:481 E:485 ||| VBZ
recently  ||| S:485 E:494 ||| RB
been  ||| S:494 E:499 ||| VBN
highlighted ||| S:499 E:510 ||| VBN
.  ||| S:510 E:512 ||| .
Intrauterine  ||| S:512 E:525 ||| JJ
growth  ||| S:525 E:532 ||| NN
retardation  ||| S:532 E:544 ||| NNS
( ||| S:544 E:545 ||| -LRB-
IUGR ||| S:545 E:549 ||| NNP
)  ||| S:549 E:551 ||| -RRB-
leads  ||| S:551 E:557 ||| VBZ
to  ||| S:557 E:560 ||| TO
many  ||| S:560 E:565 ||| JJ
disorders  ||| S:565 E:575 ||| NNS
after  ||| S:575 E:581 ||| IN
maturation ||| S:581 E:591 ||| NN
,  ||| S:591 E:593 ||| ,
such  ||| S:593 E:598 ||| JJ
as  ||| S:598 E:601 ||| IN
obesity ||| S:601 E:608 ||| NN
,  ||| S:608 E:610 ||| ,
glucose  ||| S:610 E:618 ||| JJ
intolerance ||| S:618 E:629 ||| NN
,  ||| S:629 E:631 ||| ,
and  ||| S:631 E:635 ||| CC
osteoporosis ||| S:635 E:647 ||| NN
.  ||| S:647 E:649 ||| .
IUGR  ||| S:649 E:654 ||| NNP
also  ||| S:654 E:659 ||| RB
reduces  ||| S:659 E:667 ||| VBZ
pancreatic  ||| S:667 E:678 ||| CD
/  ||| S:678 E:680 ||| CD
cell  ||| S:680 E:685 ||| NN
mass ||| S:685 E:689 ||| NN
.  ||| S:689 E:691 ||| .
One  ||| S:691 E:695 ||| CD
of  ||| S:695 E:698 ||| IN
the  ||| S:698 E:702 ||| DT
underlying  ||| S:702 E:713 ||| JJ
mechanisms  ||| S:713 E:724 ||| NN
is  ||| S:724 E:727 ||| VBZ
epigenetic  ||| S:727 E:738 ||| JJ
modification ||| S:738 E:750 ||| NN
,  ||| S:750 E:752 ||| ,
such  ||| S:752 E:757 ||| JJ
as  ||| S:757 E:760 ||| IN
the  ||| S:760 E:764 ||| DT
reduction  ||| S:764 E:774 ||| NN
of  ||| S:774 E:777 ||| IN
histone  ||| S:777 E:785 ||| JJ
acetylation  ||| S:785 E:797 ||| NN
and  ||| S:797 E:801 ||| CC
increase  ||| S:801 E:810 ||| NN
of  ||| S:810 E:813 ||| IN
methylation  ||| S:813 E:825 ||| NN
in  ||| S:825 E:828 ||| IN
the  ||| S:828 E:832 ||| DT
promoter  ||| S:832 E:841 ||| NN
region  ||| S:841 E:848 ||| NN
of  ||| S:848 E:851 ||| IN
the  ||| S:851 E:855 ||| DT
Pdx1  ||| S:855 E:860 ||| JJ
gene ||| S:860 E:864 ||| NN
,  ||| S:864 E:866 ||| ,
which  ||| S:866 E:872 ||| WDT
encodes  ||| S:872 E:880 ||| VBZ
an  ||| S:880 E:883 ||| DT
important  ||| S:883 E:893 ||| JJ
transcription  ||| S:893 E:907 ||| JJ
factor  ||| S:907 E:914 ||| NN
for  ||| S:914 E:918 ||| IN
pancreatic  ||| S:918 E:929 ||| JJ
beta-cell  ||| S:929 E:939 ||| JJ
function ||| S:939 E:947 ||| NN
,  ||| S:947 E:949 ||| ,
leading  ||| S:949 E:957 ||| VBG
to  ||| S:957 E:960 ||| TO
the  ||| S:960 E:964 ||| DT
reduction  ||| S:964 E:974 ||| NN
of  ||| S:974 E:977 ||| IN
Pdx1  ||| S:977 E:982 ||| CD
expression  ||| S:982 E:993 ||| NN
levels ||| S:993 E:999 ||| NNS
.  ||| S:999 E:1001 ||| .
Numerous  ||| S:1001 E:1010 ||| JJ
susceptibility  ||| S:1010 E:1025 ||| JJ
genes  ||| S:1025 E:1031 ||| NNS
for  ||| S:1031 E:1035 ||| IN
type  ||| S:1035 E:1040 ||| NN
2  ||| S:1040 E:1042 ||| CD
diabetes ||| S:1042 E:1050 ||| NN
,  ||| S:1050 E:1052 ||| ,
including  ||| S:1052 E:1062 ||| VBG
KCNQ1 ||| S:1062 E:1067 ||| NNP
,  ||| S:1067 E:1069 ||| ,
have  ||| S:1069 E:1074 ||| VBP
been  ||| S:1074 E:1079 ||| VBN
identified  ||| S:1079 E:1090 ||| VBN
in  ||| S:1090 E:1093 ||| IN
humans  ||| S:1093 E:1100 ||| NNS
using  ||| S:1100 E:1106 ||| VBG
genome-wide  ||| S:1106 E:1118 ||| JJ
analyses  ||| S:1118 E:1127 ||| NNS
and  ||| S:1127 E:1131 ||| CC
other  ||| S:1131 E:1137 ||| JJ
related  ||| S:1137 E:1145 ||| JJ
studies ||| S:1145 E:1152 ||| NNS
.  ||| S:1152 E:1154 ||| .
The  ||| S:1154 E:1158 ||| DT
Kcnq1  ||| S:1158 E:1164 ||| JJ
locus  ||| S:1164 E:1170 ||| NN
is  ||| S:1170 E:1173 ||| VBZ
an  ||| S:1173 E:1176 ||| DT
imprinting  ||| S:1176 E:1187 ||| JJ
gene ||| S:1187 E:1191 ||| NN
.  ||| S:1191 E:1193 ||| .
Noncoding  ||| S:1193 E:1203 ||| NNP
RNA  ||| S:1203 E:1207 ||| NNP
Kcnq1ot1  ||| S:1207 E:1216 ||| NNP
is  ||| S:1216 E:1219 ||| VBZ
expressed  ||| S:1219 E:1229 ||| VBN
from  ||| S:1229 E:1234 ||| IN
the  ||| S:1234 E:1238 ||| DT
Kcnq1  ||| S:1238 E:1244 ||| CD
locus  ||| S:1244 E:1250 ||| NNS
and  ||| S:1250 E:1254 ||| CC
regulates  ||| S:1254 E:1264 ||| VBZ
the  ||| S:1264 E:1268 ||| DT
expression  ||| S:1268 E:1279 ||| NN
of  ||| S:1279 E:1282 ||| IN
neighboring  ||| S:1282 E:1294 ||| JJ
genes  ||| S:1294 E:1300 ||| NNS
on  ||| S:1300 E:1303 ||| IN
the  ||| S:1303 E:1307 ||| DT
paternal  ||| S:1307 E:1316 ||| JJ
allele ||| S:1316 E:1322 ||| NN
.  ||| S:1322 E:1324 ||| .
We  ||| S:1324 E:1327 ||| PRP
found  ||| S:1327 E:1333 ||| VBD
that  ||| S:1333 E:1338 ||| DT
disruption  ||| S:1338 E:1349 ||| NN
of  ||| S:1349 E:1352 ||| IN
Kcnq1  ||| S:1352 E:1358 ||| CD
results  ||| S:1358 E:1366 ||| NNS
in  ||| S:1366 E:1369 ||| IN
reduced  ||| S:1369 E:1377 ||| JJ
expression  ||| S:1377 E:1388 ||| NN
of  ||| S:1388 E:1391 ||| IN
Kcnqlot1  ||| S:1391 E:1400 ||| CD
as  ||| S:1400 E:1403 ||| IN
well  ||| S:1403 E:1408 ||| RB
as  ||| S:1408 E:1411 ||| IN
increased  ||| S:1411 E:1421 ||| JJ
expression  ||| S:1421 E:1432 ||| NN
of  ||| S:1432 E:1435 ||| IN
Cdkn1c ||| S:1435 E:1441 ||| NNP
,  ||| S:1441 E:1443 ||| ,
an  ||| S:1443 E:1446 ||| DT
imprinted  ||| S:1446 E:1456 ||| JJ
gene  ||| S:1456 E:1461 ||| NN
that  ||| S:1461 E:1466 ||| IN
encodes  ||| S:1466 E:1474 ||| VBG
a  ||| S:1474 E:1476 ||| DT
cell  ||| S:1476 E:1481 ||| NN
cycle  ||| S:1481 E:1487 ||| NN
inhibitor  ||| S:1487 E:1497 ||| VBZ
only  ||| S:1497 E:1502 ||| RB
when  ||| S:1502 E:1507 ||| WRB
the  ||| S:1507 E:1511 ||| DT
mutation  ||| S:1511 E:1520 ||| NN
is  ||| S:1520 E:1523 ||| VBZ
on  ||| S:1523 E:1526 ||| IN
the  ||| S:1526 E:1530 ||| DT
paternal  ||| S:1530 E:1539 ||| JJ
allele ||| S:1539 E:1545 ||| NN
.  ||| S:1545 E:1547 ||| .
Furthermore ||| S:1547 E:1558 ||| RB
,  ||| S:1558 E:1560 ||| ,
histone  ||| S:1560 E:1568 ||| JJ
modification  ||| S:1568 E:1581 ||| NN
in  ||| S:1581 E:1584 ||| IN
the  ||| S:1584 E:1588 ||| DT
Cdkn1c  ||| S:1588 E:1595 ||| JJ
promoter  ||| S:1595 E:1604 ||| NN
region  ||| S:1604 E:1611 ||| NN
in  ||| S:1611 E:1614 ||| IN
pancreatic  ||| S:1614 E:1625 ||| JJ
islets  ||| S:1625 E:1632 ||| NN
was  ||| S:1632 E:1636 ||| VBD
found  ||| S:1636 E:1642 ||| VBN
to  ||| S:1642 E:1645 ||| TO
contribute  ||| S:1645 E:1656 ||| VB
to  ||| S:1656 E:1659 ||| TO
this  ||| S:1659 E:1664 ||| DT
phenomenon ||| S:1664 E:1674 ||| NN
.  ||| S:1674 E:1676 ||| .
These  ||| S:1676 E:1682 ||| DT
results  ||| S:1682 E:1690 ||| NNS
indicate  ||| S:1690 E:1699 ||| VBP
that  ||| S:1699 E:1704 ||| IN
epigenetic  ||| S:1704 E:1715 ||| JJ
modification  ||| S:1715 E:1728 ||| NN
might  ||| S:1728 E:1734 ||| MD
be  ||| S:1734 E:1737 ||| VB
important  ||| S:1737 E:1747 ||| JJ
for  ||| S:1747 E:1751 ||| IN
the  ||| S:1751 E:1755 ||| DT
regulation  ||| S:1755 E:1766 ||| NN
of  ||| S:1766 E:1769 ||| IN
pancreatic  ||| S:1769 E:1780 ||| JJ
beta-cell  ||| S:1780 E:1790 ||| JJ
mass  ||| S:1790 E:1795 ||| NN
and  ||| S:1795 E:1799 ||| CC
the  ||| S:1799 E:1803 ||| DT
onset  ||| S:1803 E:1809 ||| NN
of  ||| S:1809 E:1812 ||| IN
diabetes ||| S:1812 E:1820 ||| NN
.  ||| S:1820 E:1822 ||| .
